Galen Chemicals entered into an agreement to acquire Pfizer’s women’s healthcare pharmaceutical products in two conditional deals that could be worth up to US$484 M to Pfizer. The deals include the acquisition of women’s health care products that includes oral contraceptives Estrostep® and Loestrin® and the hormone replacement therapy Femhrt® for an initial sum of US$359 M.